Treatment of Gout in the Primary Health Care
DOI:
https://doi.org/10.5712/rbmfc12(39)1445Keywords:
Gout. Therapeutics. Primary Health Care.Abstract
Objective: The objective of this review is to provide updated information and practical guidelines on the approach of gout in Primary Health Care. Methods: We conducted a survey of clinical guidelines, systematic reviews, meta-analyses and original studies published between January 1, 2011 and December 31, 2016 in the English, Portuguese and Spanish languages. Results: First-line drugs in the treatment of acute gout are non-steroidal anti-inflammatory drugs, colchicine and corticosteroids, in monotherapy or combination. In chronic gout, the first-line of hypouricemic therapy is allopurinol. Febuxostat and uricosurics are alternatives to allopurinol in cases of intolerance or ineffectiveness. The prophylaxis of acute attacks is recommended when starting hypouricemic treatment for at least 6 months. Treatment of asymptomatic hyperuricemia is not recommended. Conclusion: The correct approach to gout should be part of the skills of a Primary Care physician in order to provide adequate care to the community.
Downloads
Metrics
References
Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012;64(10):1431-46. DOI: http://dx.doi.org/10.1002/acr.21772 DOI: https://doi.org/10.1002/acr.21772
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. DOI: http://dx.doi.org/10.1136/annrheumdis-2016-209707 DOI: https://doi.org/10.1136/annrheumdis-2016-209707
Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al.; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012;64(10):1447-61. DOI: http://dx.doi.org/10.1002/acr.21773 DOI: https://doi.org/10.1002/acr.21773
Miguel C, Mediavilla MJ. Current management of gout. Acta Med Port. 2011;24(5):791-8.
Moi JH, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for acute gout. Cochrane Database Syst Rev. 2013;(11):CD010519. DOI: http://dx.doi.org/10.1002/14651858
van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, van der Heijde D, Landewé RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014;(9):CD010120. DOI: http://dx.doi.org/10.1002/14651858
van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. Cochrane Database Syst Rev. 2014;(8):CD006190. DOI: http://dx.doi.org/10.1002/14651858
Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008;(2):CD005521. DOI: http://dx.doi.org/10.1002/14651858
Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103-8. DOI: 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C DOI: https://doi.org/10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C
Mead T, Arabindoo K, Smith B. Managing gout: there’s more we can do. J Fam Pract. 2014;63(12):707-13.
Sivera F, Wechalekar MD, Andrés M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev. 2014(9):CD009993. DOI: http://dx.doi.org/10.1002/14651858
Rothschild BM. Gout and Pseudogout Treatment & Management. Medscape 2016. [citado 2016 Dez 31]. Disponível em: http://emedicine.medscape.com/article/329958-treatment?src=refgatesrc1#d10
Moi JH, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for chronic gout. Cochrane Database Syst Rev. 2013;(5):CD010039. DOI: http://dx.doi.org/10.1002/14651858 DOI: https://doi.org/10.1002/14651858
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.
